KPIs & Operating Metrics(New)
Breakdown Of AssetsEmployee StatisticsGastroenterology Revenue By CategoryGastroenterology Revenue By Category AnnualHereditary Angioedema By Category AnnualNeuroscience Revenue By CategoryNeuroscience Revenue By Category AnnualNon Current Assets By Geography AnnualNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Oncology Revenue By CategoryOncology Revenue By Category AnnualOpex As A % Of Total Revenue %OPEX SegregationOther Revenue By CategoryOther Revenue By Category AnnualPdt Immunology Revenue By CategoryPdt Immunology Revenue By Category AnnualProperty, Plant And Equipment, Net BreakdownRare Genetics And Other Revenue By CategoryRare Hematology Revenue By CategoryRare Hematology Revenue By Category AnnualRare Metabolic Revenue By Category AnnualRemaining Performance ObligationsRevenue By Category Rare DiseasesRevenue By RegionRevenue By Region %Revenue By Region AnnualRevenue By Region Annual %Revenue By Therapeutic AreaRevenue By Therapeutic Area %Revenue By Therapeutic Area AnnualRevenue By Therapeutic Area Annual %Revenue By Type Of Good Or ServiceRevenue By Type Of Good Or Service %Revenue By Type Of Good Or Service AnnualRevenue By Type Of Good Or Service Annual %
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Assets Growth (1y)Assets Growth (3y)Assets Growth (5y)Cash & Equivalents Growth (1y)Cash & Equivalents Growth (3y)Cash & Equivalents Growth (5y)Enterprise Value Growth (1y)Enterprise Value Growth (3y)Enterprise Value Growth (5y)Property, Plant & Equipment (Net) Growth (1y)Property, Plant & Equipment (Net) Growth (3y)Property, Plant & Equipment (Net) Growth (5y)Return on Assets (QoQ)Shareholder's Equity Growth (1y)Shareholder's Equity Growth (3y)Shareholder's Equity Growth (5y)Total Debt Growth (1y)Total Debt Growth (3y)Total Debt Growth (5y)
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Takeda Pharmaceutical (TAK) Shareholder's Equity Growth (3y) (2021 - 2026)
Generated on {Timestamp}
© BusinessQuant.com
Generated on {Timestamp}
Powered by 
Peer Comparison
Historic Data
Download Data 🔒| Date | Value |
|---|---|